Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SPT-300 · LYT-300

Small molecule · Acts on allopregnanolone · developed by Seaport Therapeutics

Phase 2 Most advanced trial

SPTX Developer

1 Registered trials

What is SPT-300?

SPT-300 is a prodrug of allopregnanolone, a small molecule. It is studied in major depressive disorder with and without anxious distress.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: LYT-300, GlyphAllo, Glyph Allopregnanolone
Drug type: Small molecule
Targets: allopregnanolone
Mechanism: Acts on allopregnanolone
Therapy area: Psychiatry
Developer: Seaport Therapeutics (SPTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07065240	Phase 2	Major Depressive Disorder (MDD)	Recruiting	SPTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress

Sources

ClinicalTrials.gov NCT07065240

Updated Oct 3, 2026. Something wrong or missing? Report it on the SPTX page.

Follow SPTX, the company behind SPT-300

See SPTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SPTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z